Methods Of Treating Fabry Patients Having Renal Impairment

USPTO published patent application US20260097027A1 disclosing methods for treating Fabry disease patients with renal impairment using migalastat. The application covers administration of about 150 mg migalastat hydrochloride every other day to patients harboring HEK assay amenable mutations in α-galactosidase A.

Pharmaceutical companies developing Fabry disease treatments or generic migalastat formulations should monitor this application. If granted, the patent could create exclusivity for specific dosing regimens in renally impaired populations. Competitors may need to design around these claims or challenge validity during prosecution.